CSPC Pharma (HKEx: 01093) has announced that its self-developed second-generation long-acting antipsychotic injectable, Paliperidone Palmitate Injection, has received marketing approval from China's National Medical Products Administration.

The product is available in three specifications: 0.75ml:75mg, 1.0ml:100mg, and 1.5ml:150mg (calculated as C23H27FN4O3). It is indicated for both acute and maintenance treatment of schizophrenia.

Compared to traditional antipsychotic medications, this product requires only one monthly injection and achieves rapid onset of action without the need for oral supplementation, making it suitable for treating patients in the acute phase. Additionally, the once-monthly dosing schedule significantly improves patient compliance, helps prevent missed doses, and effectively reduces the rates of disease relapse and rehospitalization.

This product is recommended in authoritative domestic and international treatment guidelines, including the Chinese Guidelines for the Prevention and Treatment of Schizophrenia (2025 Edition). It is positioned as a preferred treatment option for schizophrenic patients with poor compliance or high risk of relapse, offering substantial clinical and pharmacoeconomic value.

The approval of this product will further enrich CSPC Pharma's product portfolio in the psychiatric and neurological field. The company remains committed to developing more high-clinical-value medications to provide better treatment options for patients.